Vericel [VCEL] vs Vertex [VRTX] Detailed Stock Comparison

Vericel Corporation

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Vericel Corporation wins in 3 metrics, Vertex Pharmaceuticals Inc. wins in 17 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Vericel Corporation Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) 106.36 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 4.86 5.92 Vericel Corporation
Debt-to-Equity Ratio 27.32 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio 7.09 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA 73.87 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 5.98% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) 24.12% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) 24.12% 39.60% Vertex Pharmaceuticals Inc.
Return on Equity 5.11% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) 1.50% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $24.75M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return -19.30% 1.24% Vertex Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 6.27 9.22 Vericel Corporation
Enterprise Value $1.67B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 6.04 8.83 Vericel Corporation
Gross Profit Margin (TTM) 78.70% 85.39% Vertex Pharmaceuticals Inc.
Revenue per Share (TTM) $5 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $0.32 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 1.21 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 13.64% 1.78% Vertex Pharmaceuticals Inc.

Vericel Corporation vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

VCEL
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Vericel Corporation0.81%-1.49%-5.59%-2.57%-8.50%-3.26%
Vertex Pharmaceuticals Inc.0.76%-2.49%-1.11%-12.54%-1.86%-5.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Vericel Corporation-19.30%1.21%-40.16%1,129.89%-45.72%-84.22%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Vericel Corporation vs Vertex Pharmaceuticals Inc.

MetricVCELVRTX
Market Information
Market Cap i$1.75B$109.45B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i410,8431,057,061
90 Day Avg. Volume i683,1141,272,097
Last Close$34.73$428.34
52 Week Range$28.95 - $45.97$362.50 - $507.92
% from 52W High-24.45%-15.67%
All-Time High$1,590.00 (Sep 22, 1997)$519.88 (Nov 04, 2024)
% from All-Time High-97.82%-17.61%
Growth Metrics
Quarterly Revenue Growth0.23%0.10%
Quarterly Earnings Growth0.17%0.31%
Financial Health
Profit Margin (TTM) i0.06%0.33%
Operating Margin (TTM) i0.24%0.40%
Return on Equity (TTM) i0.05%0.23%
Debt to Equity (MRQ) i27.3210.91
Cash & Liquidity
Book Value per Share (MRQ)$7.01$73.49
Cash per Share (MRQ)$2.71$26.01
Operating Cash Flow (TTM) i$51.91M$3.63B
Levered Free Cash Flow (TTM) i$16.05M$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Vericel Corporation vs Vertex Pharmaceuticals Inc.

MetricVCEL (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i106.3628.40
Forward P/E i42.2819.95
PEG Ratio i7.090.88
Price to Sales (TTM) i6.279.22
Price to Book (MRQ) i4.865.92
Market Capitalization
Market Capitalization i$1.75B$109.45B
Enterprise Value i$1.67B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i6.048.83
Enterprise to EBITDA i73.8721.78
Risk & Other Metrics
Beta i1.210.37
Book Value per Share (MRQ) i$7.01$73.49

Financial Statements Comparison: Vericel Corporation vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricVCEL (2025)VRTX (2025)
Revenue/Sales i276.26M12.00B
Cost of Goods Sold i70.66M1.65B
COGS % of Revenue i25.6%13.8%
Gross Profit i205.60M10.35B
Gross Margin i74.4%86.2%
Research & Development i27.56M4.04B
Operating Income (EBIT) i11.04M4.55B
Operating Margin i4.0%37.9%
EBITDA i29.55M5.25B
EBITDA Margin i10.7%43.7%
Pre-Tax Income i17.38M4.64B
Pre-Tax Income % of Revenue i6.3%38.7%
Income Tax i859,000690.00M
Income Tax % of Revenue i0.3%5.7%
Net Income (Profit) i16.52M3.95B
Profit Margin i6.0%32.9%

Balance Sheet & Liquidity Metrics

MetricVCEL (2025)VRTX (2025)
Cash & Equivalents i100.09M5.08B
Total Current Assets i247.44M11.20B
Total Current Assets % of Revenue i89.6%93.3%
Total Current Liabilities i49.15M3.86B
Total Current Liabilities % of Revenue i17.8%32.2%
Long-Term Debt i82.28M1.95B
Long-Term Debt % of Revenue i29.8%16.3%
Total Shareholders Equity i354.64M18.67B
Retained Earnings i-376.30M13.56B
Retained Earnings % of Revenue i-136.2%113.0%
Property, Plant & Equipment i64.77M1.56B

Cash Flow Statement Comparison

MetricVCEL (2025)VRTX (2025)
Operating Cash Flow i48.88M3.77B
Operating Cash Flow % of Revenue i17.7%31.4%
Capital Expenditures iN/A-437.60M
Free Cash Flow i24.75M3.19B
FCF Margin i9.0%26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricVCELVRTX
Shares Short i5.38M4.02M
Short Ratio i7.612.80
Short % of Float i13.64%1.78%
Shares Outstanding i50.62M253.99M
Float Shares i47.58M253.24M
% Held by Insiders i1.47%0.21%
% Held by Institutions i110.80%97.60%
% Held by Public i-12.27%2.19%

Dividend Analysis & Yield Comparison: Vericel Corporation vs Vertex Pharmaceuticals Inc.

MetricVCELVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A